(2-(1H-四唑-5-基)-[1,1-二联苯]-4-基)甲胺 | 147225-68-1

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-(1H-四唑-5-基)-[1,1-二联苯]-4-基)甲胺
• 英文名称: (2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methanamine
• 英文别名: 4'-aminomethyl-2-(1H-tetrazol-5-yl)biphenyl；N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amine；[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methanamine
• CAS: 147225-68-1
• 化学式: C₁₄H₁₃N₅
• 分子量: 251.291
• InChiKey: QSRSXEHFQCQDRK-UHFFFAOYSA-N

物化性质

• 熔点：
  >225°C (dec.)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  80.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-(1H-四唑-5-基)-[1,1-二联苯]-4-基)甲胺 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 0.67h， 生成 3-(3-Morpholin-4-yl-propyl)-1-naphthalen-2-ylmethyl-1-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-thiourea
  参考文献：
  名称：

  Novel simple thioureas with growth hormone releasing properties

  摘要：

  A series of thioureas containing two aromatic groups and one amino group was synthesized as potential growth hormone secretagogues. The growth hormone (GH) releasing properties of these compounds (10-24) were evaluated using primary rat pituitary cells. The most potent compound 20 showed potency with an EC50 of 1.8 mu M. Two constrained analogs 23 and 24 showed similar activity.

  DOI：

  10.1016/s0223-5234(97)83289-8
• 作为产物：
  描述：

  2,2,2-trifluoro-N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)acetamide 在 氢氧化钾 、 水 、 盐酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.0h， 以60%的产率得到(2-(1H-四唑-5-基)-[1,1-二联苯]-4-基)甲胺
  参考文献：
  名称：

  [EN] NOVEL PYRROLE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY
  [FR] DERIVES DE PYRROLE POSSEDANT UNE ACTIVITE ANTAGONISTE DE L'ANGIOTENSINE II

  摘要：

  公开号：

  WO2005105789A3

文献信息

• Substituted quinazolines as angiotensin II antagonists
  申请人：American Home Products Corporation

  公开号：US05187168A1

  公开（公告）日：1993-02-16

  There are disclosed compounds of the general formula I: ##STR1## wherein A is --CR.sup.7 .dbd.CR.sup.8 --; Z is --CR.sup.7 .dbd.CR.sup.8 --; X is H, NR .sup.9 R.sup.10, OR.sup.11, CN, F, Cl, I, Br, perfluoroalkyl, alkyl,alkoxy, alkyl-OH, alkoxyalkyl, --(CH.sub.2).sub.n CO.sub.2 R.sup.11,--(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; Y is NR.sup.13,NR.sup.13 CR.sup.12 R.sup.14, CR.sup.12 R.sup.14 NR.sup.13 ; R.sup.1 is 5-tetrazolyl, CO.sub.2 R.sup.11,SO.sub.3 H, NHSO.sub.2 CH.sub.3, NHSO.sub.2 CF.sub.3 ; R.sup.2,R.sup.3,R.sup.4,R.sup.7 R.sup.8 is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO.sub.2, SO.sub.2 R.sup.13, --(CH.sub.2).sub.n CO.sub.2 R.sup.11,--(CH.sub.2).sub.n CONR.sup.9 R.sup.10, OR.sup.11,F,Cl,Br,I,NR.sup.9 R.sup.10 ; R.sup.5 is alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, --CN, NO.sub.2, SO.sub.2 R.sup.13,--(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10, --OH,OR.sup.11,F,Cl,Br,I,NR.sup.9 R.sup.10 ; R.sup.9,R.sup.10 is H, alkyl, alkoxyalkyl,alkyl-OH, perfluoroalkyl, aralkyl; R.sup.11 is H, alkyl, aralkyl, alkoxyalkyl; R.sup.12,R.sup.14 is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO.sub.2, SO.sub.2 R.sup.13, --(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; R.sup.13 is H, OR.sup.11, alkyl, perfluoroalkyl, aralkyl, --(CH.sub.2).sub.n CO.sub.2 R.sup.11,--(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; wherein alkyl is defined as 1-8 carbons, branched or straight chain; perfluoroalkyl is defined as 1-6 carbons; aralkyl is defined as 7-12 carbons or 7-12 carbons substituted with fluorine, bromine or chlorine and the phamaceutically acceptable salts, solvates and hydrates thereof, which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension and congestive heart-failure. The compounds are also useful for reducing lipid levels in the blood plasma and are thus useful for treating hyperlipidemia and hypercholesterolemia. Also disclosed are processes for the production of said compounds and pharmaceutical compositions containing said compounds.

  公开了一般式I的化合物：##STR1##其中A为--CR.sup.7 .dbd.CR.sup.8--; Z为--CR.sup.7 .dbd.CR.sup.8--; X为H、NR .sup.9 R.sup.10、OR.sup.11、CN、F、Cl、I、Br、全氟烷基、烷基、烷氧基、烷基-OH、烷氧基烷基、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10；Y为NR.sup.13、NR.sup.13 CR.sup.12 R.sup.14、CR.sup.12 R.sup.14 NR.sup.13；R.sup.1为5-四唑基、CO.sub.2 R.sup.11、SO.sub.3 H、NHSO.sub.2 CH.sub.3、NHSO.sub.2 CF.sub.3；R.sup.2、R.sup.3、R.sup.4、R.sup.7、R.sup.8为H、烷基、烷氧基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、CN、NO.sub.2、SO.sub.2 R.sup.13、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10、OR.sup.11、F、Cl、Br、I、NR.sup.9 R.sup.10；R.sup.5为烷基、烷氧基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、H、--CN、NO.sub.2、SO.sub.2 R.sup.13、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10、--OH、OR.sup.11、F、Cl、Br、I、NR.sup.9 R.sup.10；R.sup.9、R.sup.10为H、烷基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基；R.sup.11为H、烷基、芳基烷基、烷氧基烷基；R.sup.12、R.sup.14为H、烷基、烷氧基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、CN、NO.sub.2、SO.sub.2 R.sup.13、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10；R.sup.13为H、OR.sup.11、烷基、全氟烷基、芳基烷基、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10；其中烷基定义为1-8个碳原子，支链或直链；全氟烷基定义为1-6个碳原子；芳基烷基定义为7-12个碳原子或7-12个碳原子取代氟、溴或氯，以及其药用可接受的盐、溶剂化合物和水合物，由于其拮抗血管紧张素II的能力，可用于治疗高血压和充血性心力衰竭。这些化合物还可用于降低血浆中的脂质水平，因此可用于治疗高脂血症和高胆固醇血症。还公开了制备该化合物的方法和含有该化合物的药物组合物。
• Synthesis and antimicrobial activity of new urea and thiourea derivatives of (2′-(1H-tetrazol-5-yl)biphenyl-4-yl)methanamine
  作者：Pandreti Vedavathi、Hasti Sudhamani、Chamarthi Naga Raju

  DOI：10.1007/s11164-016-2823-1

  日期：2017.5

  Abstract Synthesis of a series of novel urea and thiourea derivatives of (2′-(1 H -tetrazol-5-yl)biphenyl-4-yl)methanamine (valsartan intermediate) ( 1 ) was accomplished by reaction of 1 with various substituted aryl isocyanates and aryl isothiocyanates in presence of N , N -dimethylpiperazine (DMP). All synthesized compounds were evaluated for their antibacterial and antifungal activities and their

  摘要通过 1 与各种取代的芳基反应，完成 了一系列新的（2'-（1 H- 四唑-5-基）联苯-4-基）甲胺（缬沙坦中间体）（ 1 ）的 脲和硫脲衍生物的 合成 N ， N- 二甲基哌嗪（DMP）的存在下，生成异氰酸酯和异硫氰酸芳基酯 。评价所有合成的化合物的抗菌和抗真菌活性，并确定其最低抑菌浓度（MIC）值。一些标题化合物对 金黄色葡萄球菌 ， 铜绿假单胞菌 和 大肠杆菌 具有良好的体外抗菌活性。 。标题化合物还显示出高的抗真菌活性。通过红外（IR），1 H和13 C核磁共振（NMR）和质谱数据表征标题化合物。 图形概要
• Process for Preparing an Angiotensin II Receptor Antagonist
  申请人：Bessa Belmunt Jordi

  公开号：US20080281097A1

  公开（公告）日：2008-11-13

  Process for preparing angiotensin II receptor antagonists, in particular irbesartan, protected forms for the preparation thereof, or a pharmaceutically acceptable salt thereof, that comprises the reaction between a biphenylamino derivative and an oxazolone derivative. New intermediates are useful for the preparation of angiotensin II receptor antagonists.

  制备血管紧张素II受体拮抗剂（特别是厄贝沙坦）的过程，其保护形式的制备，或其药学上可接受的盐，包括联苯胺衍生物和噁唑烷衍生物之间的反应。新的中间体对于制备血管紧张素II受体拮抗剂是有用的。
• Novel Pyrrole Derivatives with Angiotensin II Antagonist Activity
  申请人：Makovec Francesco

  公开号：US20070244170A1

  公开（公告）日：2007-10-18

  Compounds which may be represented by the general formula (I) shown below and in which: R 1 is a group independently selected from among: CHO, —COOH, —CH 2 OH R 2 is hydrogen or a linear or branched C 1 -C 6 alkyl group R 3 is hydrogen or a halogen group selected from among Cl and Br R 4 is a linear or branched C 3 -C 5 alkyl group and the pharmaceutically acceptable salts thereof such as the sodium or potassium salt. The compounds exhibit potent and selective All antagonist activity and are useful for the treatment of any disorders in which elevated synthesis of All or overexpression of the AT 1 receptor may play a primary pathological role, as in the case of arterial hypertension, congestive cardiac insufficiency, platelet aggregation and disorders associated therewith such as for example myocardial and cerebral infarction, renal ischaemia, venous and arterial thrombosis, peripheral vasculopathy, pulmonary hypertension, diabetes mellitus, diabetic neuropathy, glaucoma and diabetic retinopathy.

  化合物可以用下面的通式（I）表示，其中：R1是从以下组中独立选择的一组：CHO，—COOH，—CH2OH；R2是氢或线性或支链的C1-C6烷基；R3是氢或从Cl和Br中选择的卤素基团；R4是线性或支链的C3-C5烷基团，以及其药学上可接受的盐，例如钠盐或钾盐。这些化合物表现出强效和选择性的All拮抗活性，并且可用于治疗任何升高的All合成或AT1受体过度表达可能起主要病理作用的疾病，例如动脉高血压、充血性心力衰竭、血小板聚集和与之相关的疾病，例如心肌梗死和脑梗死、肾缺血、静脉和动脉血栓形成、周围血管病、肺动脉高压、糖尿病、糖尿病神经病变、青光眼和糖尿病性视网膜病变。
• Pyrrole derivatives with angiotensin II antagonist activity
  申请人：Rottapharm S.p.A.

  公开号：US07906501B2

  公开（公告）日：2011-03-15

  Compounds which may be represented by the general formula (I) shown below and in which: R1 is a group independently selected from among: CHO, —COOH, —CH2OH R2 is hydrogen or a linear or branched C1-C6 alkyl group R3 is hydrogen or a halogen group selected from among Cl and Br R4 is a linear or branched C3-C5 alkyl group and the pharmaceutically acceptable salts thereof such as the sodium or potassium salt. The compounds exhibit potent and selective All antagonist activity and are useful for the treatment of any disorders in which elevated synthesis of All or overexpression of the AT1 receptor may play a primary pathological role, as in the case of arterial hypertension, congestive cardiac insufficiency, platelet aggregation and disorders associated therewith such as for example myocardial and cerebral infarction, renal ischaemia, venous and arterial thrombosis, peripheral vasculopathy, pulmonary hypertension, diabetes mellitus, diabetic neuropathy, glaucoma and diabetic retinopathy.

  化合物可以用下面的通式（I）表示，其中：R1是从以下组中独立选择的一组：CHO，-COOH，-CH2OH；R2是氢或线性或支链的C1-C6烷基；R3是氢或从Cl和Br中选择的卤素基团；R4是线性或支链的C3-C5烷基；以及其药学上可接受的盐，如钠盐或钾盐。这些化合物具有强效且选择性的All拮抗剂活性，适用于治疗任何升高的All合成或AT1受体过度表达可能起主要病理作用的疾病，例如动脉高血压、充血性心力衰竭、血小板聚集及相关疾病，如心肌和脑梗塞、肾缺血、静脉和动脉血栓形成、周围血管病变、肺动脉高压、糖尿病、糖尿病神经病变、青光眼和糖尿病视网膜病变。